• Free Book
  • Store
    • Books
    • Free First Chapters
    • Free Newsletters
  • Recent Articles

TradingMarkets.com

Quantified Stock Market Trading Strategies & Systems

  • Home
  • New Trading Research
  • Education
    • Articles
      • Connors Research
      • ETFs
      • Options
      • Stocks
      • Volatility
      • Contributors
        • Larry Connors
        • Kevin Haggerty
        • Matt Radtke
    • Trading Lessons
    • Connors Research
    • Glossary
    • Interview Archive
    • Videos
  • Python
  • Quantamentals
    • Quantamentals: The Next Great Forefront of Trading and Investing
    • Quantamentals Resources
  • Courses
  • Store
    • New Book! The Alpha Formula
    • “Buy The Fear, Sell The Greed” – Best Seller!
    • Swing Trading College 2019
    • Trading Books and Guidebooks
    • Street Smarts
    • Online Trading Courses
    • Private Mentoring with Larry Connors
    • Customized Trading Research
    • Amibroker Strategy Add On Modules
Home » The Celebrex Boost

The Celebrex Boost

February 2, 1999 by Paul Ruggieri

Monsanto’s stock rose 8 5/16 to 47 9/16 the last week of January on news of strong
initial sales of its new arthritis drug Celebrex.
Demand was high, with close to 10,000 prescriptions generated
during the first week of availability. This number was far greater than any
other new drug offering in recent memory outside of Pfizer’s Viagra.

Doctors are very enthusiastic about this new class of pain
medication, and many patients seem to be as well. Arthritis-induced pain is a
common problem and the market for a new class of drugs like Celebrex
(devoid of unwanted gastrointestinal side affects) is huge. (My mother, who suffers from arthritic pain but was unable to use traditional
medications like aspirin or Motrin because of side effects, has
tried Celebrex and is excited about it.)

As soon as Pfizer and Monsanto start heavy marketing to
physicians, the sales of Celebrex should climb even higher. When Monsanto
updates its prescription sales for Celebrex in the very near future, the stock
will get an even more substantial jolt.

Next scheduled article: Monday, February 22, 1999. “New Technology: Companies unraveling the genetic code to battle disease–the Internet stocks of the biotechnology field.”

Filed Under: Recent, Trading Lessons

Beginner's Guide to Python

new Book By Larry Connors and Chris Cain, CMT

The Alpha Formula

Buy The Fear, Sell The Greed

Buy The Fear, Sell The Greed

Programming in Python For Traders

Programming in Python For Traders

Company Info

The Connors Group, Inc.
185 Hudson St., Suite 2500
Jersey City, NJ 07311
www.cg3.com

About Us

About
Careers
Contact Us
Link To Us

Company Resources

Help
Privacy Policy
Return Policy
Terms & Conditions

Properties

TradingMarkets
Connors Research

Connect with TradingMarkets

Contact

info@cg3.com
973-494-7311 ext. 628

Free Book

Short Term Trading Strategies That Work

© Copyright 2020 The Connors Group, Inc.

Copyright © 2021 · News Pro Theme on Genesis Framework · WordPress · Log in

TradingMarkets.com logoTradingMarkets.com supplies active traders with the education and tools they need to make trades based on data - not emotion and delivers content, tools, data, and trading systems aligned with the proprietary trading methodologies developed by Connors Research. Learn more about our products and services here!